protein tyrosine phosphatase receptor type OGenealiases: GLEPP1 · NPHS6 · PTP-OC · PTP-U2 · PTPROT · PTPU2
Q-omics provides the consensus-scored PTPRO profile across patient tissues and cancer cell-line models. PTPRO expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PTPRO is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, PTPRO RNA expression shows 18,325 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, LUAD, and UVM as cancer lineages where PTPRO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPRO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPRO survival associations across molecular data types. PTPRO RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPRO RNA expression–survival associations across cancer types. High PTPRO expression shows unfavorable associations in LIHC and LAML, but favorable associations in SKCM, KIRC, UCS and KIRP. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PTPRO RNA expression.
This table summarizes PTPRO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPRO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPRO shows lower tumor expression in LUAD, KIRC, KIRP and LUSC and higher tumor expression in HNSC and THCA. The LUAD box plot shows higher PTPRO RNA expression in normal versus tumor tissue (log2 FC = −1.544, t-test p < 0.001).
This table shows molecular features associated with PTPRO in patient tissues and cancer cell lines. In patient samples, PTPRO shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPRO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
